Brainsway Ltd. ADR logo

Brainsway Ltd. ADR (BWAY)

Market Closed
30 Jul, 20:00
NASDAQ (NMS) NASDAQ (NMS)
$
15. 25
+1.09
+7.6977%
$
598.15M Market Cap
- P/E Ratio
- Div Yield
81,348 Volume
-0.03 Eps
$ 14.16
Previous Close
Investors:
Add Transaction
Day Range
14.65 15.46
Year Range
5.68 17.35
Want to track BWAY and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

BWAY closed today higher at $15.25, an increase of 7.6977% from yesterday's close, completing a monthly decrease of -1.1666% or -$0.18. Over the past 12 months, BWAY stock lost -20.3239%.
BWAY is not paying dividends to its shareholders.
The last earnings report, released on May 11, 2026, exceeded the consensus estimates by 0%. On average, the company has fell short of earnings expectations by -0.0367%, based on the last three reports.
Brainsway Ltd. ADR has completed 2 stock splits, with the recent split occurring on Mar 04, 2026.
The company's stock is traded on one exchange.

BWAY Chart

People also search for

Aurinia Pharmaceuticals Inc.
$ 15
-1.1858%
GH Research plc
$ 28.38
+1.4296%
Ocular Therapeutix Inc.
$ 8.47
+1.3158%
Eventide Healthcare & Life Sciences Fund Class A Shares
$ 54.78
+2.8926%
Kardigan, Inc.
$ 20.47
+3.7506%
Brainsway (BWAY) is on the Move, Here's Why the Trend Could be Sustainable

Brainsway (BWAY) is on the Move, Here's Why the Trend Could be Sustainable

Brainsway (BWAY) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Zacks | 1 week ago
4 Medical Products Stocks Poised to Win Despite Industry Headwinds

4 Medical Products Stocks Poised to Win Despite Industry Headwinds

Terumo, QuidelOrtho, Lumexa Imaging and BrainsWay are tackling industry headwinds through innovation, pricing and execution as healthcare demand stays resilient.

Zacks | 1 week ago
Best Momentum Stocks to Buy for July 14th

Best Momentum Stocks to Buy for July 14th

BWAY, HTLD and NCNO made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 14th, 2026.

Zacks | 2 weeks ago

Brainsway Ltd. ADR Investors

Name Quantity Cost Value Profit ($) Gain (%)
YL
Yosef Levy Y.D. More Investments Ltd.
272,004 $2.59M $4.49M $1.9M 73.5%
Kevin Bresler
Kevin Bresler TD Waterhouse Canada Inc.
1,430 $19,391 $22,837.1 $3,446.1 17.77%
BWL
Basepoint Wealth LLC Basepoint Wealth LLC
600 $5,706 $9,774 $4,068 71.29%

Brainsway Ltd. ADR (BWAY) FAQ

What is the stock price today?

The current price is $15.25.

On which exchange is it traded?

Brainsway Ltd. ADR is listed on NASDAQ (NMS).

What is its stock symbol?

The ticker symbol is BWAY.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 598.15M.

Has Brainsway Ltd. ADR ever had a stock split?

Brainsway Ltd. ADR had 2 splits and the recent split was on Mar 04, 2026.

Brainsway Ltd. ADR Profile

Health Care Technology Industry
Healthcare Sector
Hadar Levy CEO
NASDAQ (NMS) Exchange
10501L106 CUSIP
IL Country
129 Employees
- Last Dividend
4 Mar 2026 Last Split
6 Oct 1999 IPO Date

Overview

BrainsWay Ltd. is a pioneering medical technology company focused on developing and providing noninvasive neurostimulation treatments for a variety of mental health disorders. Founded in 2003 and based in Jerusalem, Israel, the company has made significant strides in offering innovative healthcare solutions not only in the United States but also on an international scale. BrainsWay is dedicated to improving the lives of individuals suffering from mental health issues through its advanced Deep Transcranial Magnetic Stimulation (dTMS) platform technology. This commitment extends to a vast clientele including doctors, hospitals, and medical centers that specialize in psychiatry.

Products and Services

BrainsWay Ltd. offers a broad spectrum of treatments for mental health disorders through its flagship Deep Transcranial Magnetic Stimulation (dTMS) platform technology. Each application of this technology targets specific conditions, providing a noninvasive alternative to traditional treatments. The range of disorders addressed includes:

  • Major Depressive Disorders: A treatment designed to mitigate the symptoms of depression, offering hope for patients who have not responded well to conventional treatment methods.
  • Anxious Depression: Tailored to manage the symptoms of depression accompanied by anxiety, providing a dual approach to treatment.
  • Obsessive-Compulsive Disorders (OCD): Aims at reducing the severity of OCD symptoms, offering patients a path to regain control over their compulsions and obsessions.
  • Smoking Addiction: Utilized as a therapeutic measure to help individuals overcome nicotine dependence and addiction, promoting healthier lifestyle choices.
  • Bipolar Disorders: Addresses the extreme mood swings associated with bipolar disorder, helping to stabilize emotions.
  • Post Traumatic Stress Disorders (PTSD): Offers relief for the symptoms of PTSD, aiding individuals in the coping process after traumatic events.
  • Schizophrenia: Focuses on alleviating some of the cognitive and affective symptoms related to schizophrenia, potentially improving quality of life.
  • Alzheimer's Disease: Explored as a treatment to possibly slow down or alleviate some of the cognitive decline associated with Alzheimer's disease.
  • Autism: Investigated for its potential to improve outcomes in individuals on the autism spectrum, focusing on enhancing communication abilities and behavioral symptoms.
  • Chronic Pain: A treatment option for managing chronic pain conditions, aiming to reduce pain intensity and improve daily functioning.
  • Multiple Sclerosis: Applied as a part of comprehensive care in managing symptoms associated with multiple sclerosis, potentially improving mobility and quality of life.
  • Post Stroke Rehabilitation: Implemented in the rehabilitation process post-stroke, focusing on restoring lost functions and accelerating recovery.
  • Parkinson's Diseases: Offers a treatment avenue for managing symptoms of Parkinson's disease, such as tremors and rigidity, aiming to enhance patient autonomy.

Contact Information

Address: Bynet Building
Phone: 972 2 582 4030